Clinical trials: Pneumococcal Polysaccharide Vaccine
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection in Solid Organ Transplant Recipients
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.
- Trial name
- NCT01527591
- Testing
- Pneumococcal Conjugate Vaccine 13 (PCV13)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Pneumococcal Infections
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
The purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12…
- Trial name
- NCT06838000
- Testing
- PCV21, 20vPCV
- Where
- 38 sites in United States, Estonia and 2 more
- Volunteers
- 1,268 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Streptococcal
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
The purpose of this phase IIIb study is to determine whether children who have not received a 3-dose primary vaccination with the pneumococcal conjugate vaccine before their 6 months of age, can receive the vaccine as part of a…
- Trial name
- NCT00345358
- Testing
- Synflorix, Infanrix IPV/Hib
- Where
- 10 sites in Finland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infection
Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)
The purpose of this study is to determine that revaccination of Pneumococcal Vaccine is well tolerated and produces an immune response in older adults.
- Trial name
- NCT00560950
- Testing
- pneumococcal 23v polysaccharide vaccine
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Disease
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine.
- Trial name
- NCT07794748
- Testing
- PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
- Where
- 37 sites in United States
- Volunteers
- 4,670 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients
Pneumococcal disease causes thousands of infections, such as meningitis, bloodstream infections, pneumonia, and ear infections in US annually.
- Trial name
- NCT04875858
- Testing
- ProDiax-23 (PPSV23)
- Where
- South Korea
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Healthy Controls
The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23
The purpose of this research study is to: Improve the effectiveness of vaccinations by identifying the effect of cholesterol medication, statins, on immune responses.
- Trial name
- StatVax (NCT02097589)
- Testing
- Atorvastatin, Pneumovax 23
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Florida
Infections, Streptococcal
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria
The purpose of this trial is to assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A when administered either as a booster dose or as a two dose catch-up vaccination…
- Trial name
- NCT01153893
- Testing
- Pneumococcal vaccine GSK1024850A, InfanrixTM
- Where
- Nigeria
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
This is a booster study in 2 groups of healthy children less than 3 years old to measure the reactogenicity, safety and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine, when given as a booster or as a two-dose…
- Trial name
- NCT00513409
- Testing
- Synflorix, Infanrix Hexa, Havrix
- Where
- Chile
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Vaccine Adverse Reaction
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
The purpose of this observational study is to examine the risk of adverse events following vaccination with 10 or 13-valent pneumococcal conjugate vaccine (PCV10 or PCV13) among infants or children age <59 months and 23-valent…
- Trial name
- NCT04551248
- Testing
- 10 or 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, Influenza vaccine
- Where
- South Korea
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Sungkyunkwan University
Crohns Disease
Pneumococcal Vaccination of Crohn Patients
Inflammatory bowel disease (IBD) are at increased risk of infections. This increased susceptibility to infections is due to the disease itself, but also be-cause many patients with autoimmune conditions are treated with…
- Trial name
- PneuVAC (NCT01947010)
- Testing
- Prevenar 13, Pneumovax
- Where
- Denmark
- Volunteers
- 151 people
- Sponsor
- Statens Serum Institut
HIV Infections, Pneumococcal Infections
A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subjects.
- Trial name
- NCT00000829
- Testing
- Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Streptococcus Pneumoniae Pneumonia
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07035054
- Testing
- low dose-1, low dose-2, high dose
- Where
- China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pneumonia, Streptococcus Pneumoniae
Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status
Community acquired pneumonia (CAP) is an important health problem with significant morbidity, mortality and cost. The most identified pathogen in CAP is Streptococcus pneumoniae.
- Conditions
- Pneumonia, Streptococcus Pneumoniae, Immune Response
- Trial name
- CAPolista (NCT02141009)
- Testing
- Prevnar 13
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- St. Antonius Hospital
Healthy
Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time
The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants
- Trial name
- NCT00581035
- Testing
- Prevenar and Meningitec, Prevenar, Meningitec
- Volunteers
- 712 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Nasopharyngeal Carriage of S. Pneumoniae
Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
The specific aim is to evaluate the impact of PCV13 as administered in the pediatric primary care clinic at Boston medical center on the serotype specific carriage of Streptococcus pneumoniae in children < 5.
- Trial name
- NCT01109108
- Where
- United States
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Prevention of Meningococcal Infection
Persistence of Antibody Response to N. Meningitidis Group C in Children
Persistence of Antibody Response to N. meningitidis Group C in Children
- Trial name
- NCT00316654
- Testing
- Meningococcal C conjugate vaccine
- Where
- 2 sites in Poland, Spain
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Prophylactic Pneumococcal Diseases
Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.
The purpose of this study is to evaluate the safety and immunogenicity of two doses of GSK Biologicals' 11 PCV vaccine when given to healthy subjects aged 18 to 40 years .
- Trial name
- NCT00327522
- Testing
- pneumococcal vaccine
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline